ACM
BIIB icon

Advisors Capital Management’s Biogen BIIB Stock Holding History

Advisors Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,130
Closed -$262K – 495
2024
Q2 		$262K Buy
1,130
+29
+3% +$6.3K ﹤0.01% 435
2024
Q1 		$237K Sell
1,101
-146
-12% -$34.2K ﹤0.01% 441
2023
Q4 		$323K Buy
1,247
+176
+16% +$43.2K 0.01% 393
2023
Q3 		$275K Buy
+1,071
New +$286K 0.01% 363

Other funds holding BIIB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Advisors Capital Management's BIIB Position: Q3 2024 in Review

Advisors Capital Management sold out of Biogen (BIIB) in Q3 2024, closing a stake of 1,130 shares — an estimated $262K sold.

Advisors Capital Management first reported a position in BIIB in Q3 2023 and held it in 4 quarters. The position peaked at $323K in Q4 2023. 916 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

  • Advisors Capital Management reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
  • Advisors Capital Management sold 1,130 Biogen shares in Q3 2024, an estimated $262K.
  • Advisors Capital Management first reported a position in Biogen in Q3 2023 and held it in 4 quarters.
  • Advisors Capital Management's Biogen position peaked at $323K in Q4 2023.
  • 916 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Advisors Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.